Ind-Swift Laboratories Limited Stock

Equities

INDSWFTLAB

INE915B01019

Pharmaceuticals

Delayed NSE India S.E. 06:19:58 2024-04-19 am EDT 5-day change 1st Jan Change
118.6 INR +1.76% Intraday chart for Ind-Swift Laboratories Limited -8.73% +14.53%
Sales 2022 10.52B 126M Sales 2023 12.16B 146M Capitalization 3.26B 39.06M
Net income 2022 -21M -252K Net income 2023 476M 5.7M EV / Sales 2022 1.26 x
Net Debt 2022 9.32B 112M Net Debt 2023 8.44B 101M EV / Sales 2023 0.96 x
P/E ratio 2022
-183 x
P/E ratio 2023
6.85 x
Employees 1,496
Yield 2022 *
-
Yield 2023
-
Free-Float 32.86%
More Fundamentals * Assessed data
Dynamic Chart
Ind-Swift Laboratories to Incorporate Wholly-Owned Arm in Dubai MT
Ind-Swift Laboratories Limited Announces Cessation of Sunil Deshmukh as Chief Executive Officer CI
Ind-Swift Laboratories Limited Announces Cessation of Lovekesh Mahajan as Chief Accounts Officer CI
Ind-Swift Laboratories Limited Redeems in Full, the 4245 Rated, Listed, Secured, 10% Coupon, Redeemable, Non-Convertible Debenture CI
Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited and Essix Biosciences Limited. CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
CARE Keeps BB Rating on Ind-Swift Laboratories' Long-term Financing; Rating Under Watch Developing MT
Ind-Swift Laboratories Limited Collaborates with The Council of Scientific and Industrial Research CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Ind-Swift Laboratories Limited agreed to acquire Ind-Swift Limited. CI
Ind-Swift Gets Board Nod to Secure INR6 Billion Loan from Ind-Swift Laboratories MT
India's Ind-Swift Labs to sell pharma ingredients ops for $198.5 million RE
Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 16.5 billion. CI
Ind-Swift Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
More news
1 day+1.54%
1 week-8.93%
Current month+18.17%
1 month+12.82%
3 months+10.87%
6 months+30.20%
Current year+14.29%
More quotes
1 week
114.35
Extreme 114.35
126.90
1 month
94.00
Extreme 94
138.45
Current year
93.00
Extreme 93
138.45
1 year
63.00
Extreme 63
138.45
3 years
52.65
Extreme 52.65
138.45
5 years
15.00
Extreme 15
138.45
10 years
15.00
Extreme 15
138.45
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 95-01-03
Chief Executive Officer 41 -
Director of Finance/CFO - 18-09-28
Members of the board TitleAgeSince
Chief Executive Officer 41 -
Chief Executive Officer 72 95-01-03
Director/Board Member 68 09-08-30
More insiders
Date Price Change Volume
24-04-19 118.6 +1.76% 797 633
24-04-18 116.6 -3.56% 547,465
24-04-16 120.8 -0.70% 680,502
24-04-15 121.7 -6.35% 578,261
24-04-12 130 +3.09% 900,082

Delayed Quote NSE India S.E., April 19, 2024 at 04:43 am EDT

More quotes
Ind-Swift Laboratories Limited is an India-based company. The Company is engaged in the business of manufacturing intermediates and formulations. The Company’s products or services include Advanced Intermediates. It is API partner for many organizations both in generic and innovative domains. The Company offers reference standards and impurities for various active pharmaceutical ingredients (APIs) under British Pharmacopoeia (BP), European Pharmacopoeia (EP), British Pharmacopoeia (BP) and others. Its impurity portfolio is stocked with a range of standards for supply. The Company offers reference standards and impurities for over 25 APIs. All impurities are shipped with full documentation, including a Certificate of Analysis and MSDS. The research center, spread over the area of 40,000 square feet, is engaged in developing process technology for APIs in different therapeutic categories.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. INDSWFTLAB Stock